VYNE Therapeutics Inc. 8-K

What Happened
VYNE Therapeutics (VYNE) announced that its board declared a special cash dividend in connection with its previously disclosed merger agreement with Yarrow Bioscience. The company estimates the aggregate Cash Dividend will be approximately $16.5 million, or about $0.38 per share, based on 42,989,506 common shares and equivalents outstanding as of July 9, 2026. The record date for payment is July 22, 2026; the transfer agent is scheduled to receive the funds on July 23, 2026 and distribute the cash to stockholders and warrant holders a few days later. Payment of the dividend is conditioned on the closing of the merger, which the company expects to occur on or about July 24, 2026, pending stockholder approval at a special meeting on July 16, 2026.

Key Details

• Estimated aggregate Cash Dividend: $16.5 million (approx. $0.38 per share).
• Shares used for estimate: 42,989,506 common stock and common stock equivalents (as of July 9, 2026).
• Record date: July 22, 2026; transfer agent payout scheduled July 23, 2026; distribution to holders follows within days.
• Dividend payment is conditional on the Merger closing (Merger Sub to merge into Yarrow); closing expected on/around July 24, 2026, subject to stockholder vote and other conditions.

Why It Matters
This dividend returns cash to VYNE’s stockholders and warrant holders immediately prior to the planned merger, potentially affecting shareholder value and the company’s cash position as determined under the merger agreement. The announced dollar and per‑share amounts are estimates that may be higher or lower when finalized per the Merger Agreement. Because payment is conditioned on the merger closing, if the merger does not close, the dividend will not be paid. Investors should review the company’s S‑4/proxy materials and vote materials for full details and consider the timing and conditional nature of this distribution when making investment or voting decisions.